12:00 AM
Aug 21, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sitaxsentan (TBC11251): Began Phase IIb/III testing

Icos Corp. (ICOS), Bothell, Wash.
Product: Sitaxsentan ( TBC11251)
Business: Cardiovascular
Therapeutic category: Receptor antagonist
Target: Endothelin...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >